Interim Report January - June 2008

Interim Report January - June 2008

• Group revenues from sales of goods and royalties amounted to
630 (665) MSEK. 

• Operating income amounted to 39 (318*) MSEK. 

• Revenues within the Esthetics product area amounted to 516 (537) MSEK and
operating income was 117 (389*) MSEK.

• Net income after tax amounted to 32 (284*) MSEK.

• Earnings per share amounted to 0.32 (2.86*) SEK.

April - June
• Group revenues from sales of goods and royalties amounted to 341 (365) MSEK
during the second quarter and operating income amounted to 29 (262*) MSEK.

• Net income after tax amounted to 22 (242*) MSEK during the second quarter.


* Operating income for 2007 includes the supplementary purchase sum of 200 MSEK
that Q-Med received from Medicis when Restylane Perlane™ was approved for sales
in the USA.


Queries should be addressed to:
Alexander Kotsinas, Vice President and CFO
Tel: 073-500 1111
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: 070-974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.

The product portfolio today contains: Restylane® for filling lines and folds,
creating volume and contouring the face, Macrolane™ for body shaping, Durolane™
for the treatment of osteoarthritis of the hip and knee joints, Deflux™ for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta™ for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q Med today has just over 700 coworkers, with close to 500 at the
company's head office and production facility in Uppsala, Sweden. Q-Med AB is
listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.